Ekopath Metropolis Lab Services Profile
Key Indicators
- Authorised Capital ₹ 5.10 M
as on 17-06-2024
- Paid Up Capital ₹ 5.10 M
as on 17-06-2024
- Company Age 11 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 1.67%
(FY 2023)
- Profit 1.18%
(FY 2023)
- Ebitda -5.01%
(FY 2023)
- Net Worth 27.29%
(FY 2023)
- Total Assets 21.20%
(FY 2023)
About Ekopath Metropolis Lab Services
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.10 M and a paid-up capital of Rs 5.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rakesh Agarwal, Ronica Baruah, and Nilesh Shah serve as directors at the Company.
- CIN/LLPIN
U93000MH2013PTC240481
- Company No.
240481
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 2013
- Date of AGM
11 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
Who are the key members and board of directors at Ekopath Metropolis Lab Services?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ronica Baruah  | Director | 14-Feb-2013 | Current |
| Nilesh Shah | Director | 14-Feb-2013 | Current |
| Rakesh Agarwal | Director | 18-Nov-2019 | Current |
Financial Performance of Ekopath Metropolis Lab Services.
Ekopath Metropolis Lab Services Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.67% increase. The company also saw a slight improvement in profitability, with a 1.18% increase in profit. The company's net worth Soared by an impressive increase of 27.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ekopath Metropolis Lab Services?
In 2023, Ekopath Metropolis Lab Services had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Centre For Digestive And Kidney Diseases (India) Private LimitedActive 20 years 8 monthsRakesh Agarwal is a mutual person
Amin's Pathology Laboratory Private LimitedActive 12 years 3 monthsRakesh Agarwal and Nilesh Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ekopath Metropolis Lab Services?
Ekopath Metropolis Lab Services has a workforce of 33 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ekopath Metropolis Lab Services, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ekopath Metropolis Lab Services's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
